La nouvelle infection au COVID-19 est une maladie respiratoire infectieuse sévère dont l\'agent causal a été identifié comme un nouveau virus de la famille des coronavirus, SARS-CoV-2. Comme les autres coronavirus, des études montrent un neurotropisme du COVID-19, induisant des lésions démyélinisantes comme dans le syndrome de Guillain-Barré.

Plus particulièrement, une note italienne conclue qu\'il y a un déficit significatif en vitamine D chez les patients infectés par le COVID-19.

Dans cette étude, nous avons utilisé un test de corrélation de Pearson sur des données de santé publique et météorologiques, dans le but de statuer sur une possible relation entre l\'ensoleillement et la mortalité induite par le COVID-19. Pa exemple dans la France métropolitaine continentale, la moyenne des heures d\'ensoleillement est significativement (pour une p-value de 1.532 × 10^−32^) corrélée au taux de mortalité due au COVID-19, avec un coefficient de Pearson de −0.636.

Cette corrélation établit un effet protecteur de l\'ensoleillement contre la mortalité due au COVID-19. Ce manuscrit est proposé uniquement pour une discussion académique et les hypothèses et ses conclusions doivent être confirmées par d\'autres recherches.
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1. Introduction {#sec0001}
===============

The novel coronavirus pneumonia (COVID-19) is a contagious acute respiratory infectious disease whose causative agent has been demonstrated to be a new virus of the coronavirus family, SARS-CoV-2. This illness was first evinced in December 2019 in the Seafood Market of Wuhan, Hubei Province, in southern China ([@bib0001]; [@bib0002]). Patients with the coronavirus pneumonia typically exhibit a fever, with temperature above 38° © and other symptoms such as dry cough, fatigue, dyspnea, difficulty breathing, and diarrhea ([@bib0004]; [@bib0003]; [@bib0001]; [@bib0005]). Furthermore, this diseases has a relatively high transmission rate as compared to other upper respiratory illnesses. As a result of this and other factors such as international travel and trade, the initial epidemic has turned into a pandemic in March 2020, with hundreds thousands of individuals confirmed to be infected worldwide -- and most likely millions of unreported cases ([@bib0005]).

Similar to other coronaviruses-caused illnesses ([@bib0006]), COVID-19 infection has shown some amount of neurotropism ([@bib0007]; [@bib0008]; [@bib0009]), with lesions not unlike those of the Guillain-Barré demyelination ([@bib0008]) or hemorrhagic necrotizing encephalopathy ([@bib0007]; [@bib0009]). Meanwhile, it has long been noted that in the case of Guillain-Barré syndrome, vitamin D deficiency, in relation with high latitude climates, is both a causal and a risk factor ([@bib0010]; [@bib0011]). Furthermore, a recent Italian note has demonstrated a significant vitamin D deficiency in a cohort of COVID-19 infected elderly women ([@bib0012]).

Therefore, it is important to assess the effect of vitamin D blood levels on COVID-19 infection rate and disease course, as it may offer preventative and/or curative options in the context of the ongoing pandemic.

Specifically in the context of continental metropolitan France, the correlation between sunlight exposure and SARS-CoV-2 infection will be studied in this article, by using an adjusted Pearson test applied to public health and weather data ([@bib0013]; [@bib0014]; [@bib0015]).

2. Methods {#sec0002}
==========

2.1. Study and participants {#sec0003}
---------------------------

We conducted a descriptive observational cross-sectional study in order to define a hypothetical relationship between sunlight exposure and SARS-CoV-2 infection. The source and targeted populations are the whole humanity in view of the ongoing COVID-19 pandemic. The eligible population is constituted by the residents of metropolitan continental France.

The study was conducted by a consortium of two data analysts, a MD-PhD specialized in radiology, and a medical student in clinical years. NexGen Analytics had no role in making the decision to submit manuscript to the publication, nor did it receive any fee or compensation in the context of this work. The first author vouches for the data and analyses, as well as for the fidelity of this report to the study protocol.

2.2. Enrollment {#sec0004}
---------------

We gathered COVID-19-related data from various public health and social sources ([@bib0013]; [@bib0015]). A parallel multiple group analysis was performed. We excluded the population from the non-metropolitan jurisdictions of France(Guyane, Mayotte, Martinique, Reunion, Guadeloupe, etc.), due to (1) the fact that their climates vastly differ from that of metropolitan France, and (2) the substantially lower access to healthcare in these areas. Moreover, albeit part of metropolitan France, the island of Corsica was excluded from this study because of poorer access to healthcare there than on the continent.

2.2. Outcome measures {#sec0005}
---------------------

We chose to use COVID-19 mortality rate as the primary variable to evaluate the role of SARS-CoV-2 infection in our hypothetical correlation. Sunlight exposure was evaluated by using the average annual hours of sunshine exposure, as reported by that country\'s national weather service ("Météo France") ([@bib0014]). Our null hypothesis (H~0~) was the non-correlation between average sunlight hours at the locality (X) and COVID-19 mortality rate (Y).

In order to assess the potential effect of confounding factors, we also considered (1) demographic variables (sex ratio, age, life expectancy, birth rate, death rate measured by 12/31/2019); (2) economic status (taxable income as reported assessed by 12/31/2017); (3) comorbidities (current smoking status, and prevalence of diabetes, Chronic Obstructive Pulmonary Disease, chronic renal failure prevalence, and obesity, as measured respectively by 01/21/2019, 12/31/2016, 12/31/2014, 12/31/2017, 12/31/2012); (4) healthcare access variables (availability of facilities for the elderly, physician per capita, hospital beds per capita as measured by 12/31/2017). The availability of facilities for the elderly was assessed by combining the number of beds at long-term care nursring homes with that of residences for independent seniors, and assisted care at home for people aged 75 years or more. The number of hospital beds per capita accounted for medical and surgical beds, both at public and private hospitals.

Finally, in order to further sustain our analysis, we also considered the confirmed COVID-19 infection cases as well as the number of verified recovered COVID-19 patients.

2.3. Statistical analysis {#sec0006}
-------------------------

We began by computing several descriptive statistics for each variable: arithmetic mean, sample variance, standard deviation and the corresponding confidence intervals (justified by having Shapiro-Wilk tested each of these variables). Obviously unrelated to COVID-19 mortality, the 2019 birth and death rates were kept off the analysis. Furthermore, age was also eliminated from this analysis as the national statistics in this regard are provided in the form of age classes not directly usable in the context of Pearson correlation analysis. All other variables were treated using the Pearson correlation test, and the corresponding p-value are reported here in order to assess the statistical significance of these correlations.

3. Results {#sec0007}
==========

3.1. Populations {#sec0008}
----------------

The included population gathers all 67,063,703 residents of France born before 01/01/20 ([@bib0015]). After applying the aforementioned exclusion criteria, the cardinality of our studied sample set was of 64,553,275 individuals residing in continental metropolitan France. COVID-19 infection parameters (infection rate, healed rate, mortality rate) were calculated using data reported data as of 04/25/2020 ([@bib0013]).

This population was subsequently partitioned by region of residence (NB: "region" is the largest sub-national jurisdiction of France), as summarized in [Table 1](#tbl0001){ref-type="table"} . We note that none of the resulting subgroups was found to exhibit values significantly outside of their respective confidence intervals, per a MANOVA-Wilk test performed at the 5% significance level ([Table 2](#tbl0002){ref-type="table"} ).Table 1Data for each continental metropolitan region of France.Table 1Regional code842753244432112875765293**Inhabitants (N)**8032,3772783,0393340,3792559,0735511,7475962,66212,278,2103303,5005999,9825924,8583801,7975055,651**Sex ratio**0.9460.9460.9420.9380.9490.9420.9310.9340.9270.9340.9460.916Male (%)48.648.648.548.448.748.548,248,348,148,348,647,8Female (%)51.451.451,551,651,351,551.851.751.951.751.452.2**Age**0--24y (%)29.827.628.428.228.531.632.028.926.727.829.927.425--59y (%)43.941.942.142.144.043.847.542.242.242.742.642.8\>60y (%)26.330.529.529.727.524.620.528.931.129.527.529.8**Life expectancy**83.3828282.381.980.783.881.782.782.98382.9Male80.578.978.779.379.077.581.478.379.780.179.880.0Female85.985.085.285.284.683.886.184.985.585.586.085.6**Birth rate (‰)**11.29.49.410.110.011.314.110.29.09.810.411.1**Death rate (‰)**8.710.910.610.69.79.36.110.410.910.19.210.2**Taxable income rate (%)**52.750.649.551.149.845.763.949.248.546.649.251.7**Prevalence of comor-bidities**Active smoker26.228.626.52830.130.521.325.628.128.62332.2Diabetes4.75.063.315.135.596.165.44.794.484.564.044.96COPD28.227.334.52436.737.725.827.526.529.32527.3CKD0.940.830.80.9811.071.20.920.840.940.91.01BMI \> 3013.415.11216.917.820.714.41714.813.211.812.1**Health-care**Senior assisted living beds (‰)148154156150147160140170150132180120Physicians (‰~**∘∘**~)340297321265321302396288337356289408Short-term hospital beds30,45811,46412,9059.69222.72823.96344.67212.76323.60321.71412.86421.885Hospital beds density (‰~**∘∘**~)379412386379412402364386393366338433**Sunlight exposure (accumulated, hours)**20032092.518502130.720841702.41984.61854.92150.72462.12091.22550.9**Infection**Confirmed cases906743781362251914,539765034,46020222752329222455790Infection rate (%)0.1130.1570.0410.0980.2640.1280.2810.0610.,0460.0560.0590.115Recovered cases4671223777210697274368515,8999841284201511213376Recovery rate (%)51.651.156.742.450.148.146.148.646.661.249.958.3Deceased cases1226797203355273712915578319294362314631Mortality rate (%)13.518.214.914.118.816.916.215.810.7111410.9Table 2Statistical parameters of continental metropolitan French population.Table 2ParameterSumAverageVarianceSDCI 95 %Inhabitants (nb.)64,553,275Sex ratio0.9389.354×10^−5^9.671×10^−3^0,9330,994Male (%)48.40.0670.25948.23648.723Female (%)51.60.0670.25951.43651.923Age0--24y (%)28.92.6911.6427.85829.71425--59y (%)43.22.4391.56242.20843.994\>60y (%)27.98.9522.99225.99928.999Life expectancy82.40.6970.83581.8782.981Male79.41.0931.04678.73680.05Female85.30.4240.65184.88685.813Birth rate (‰)10.51.8291.3529.64111.239Death rate (‰)9.71.7971.348.84810.435Taxable income rate (%)50.721.1644.647.77752.063Health statusCurrent smokers prevalence27.49.6123.125.4328.519Diabetic prevalence4.80.5430.7374.3325.345COPD prevalence29.221.0194.58526.28730.561Chronic kidney failure prevalence0.90.0130.1140.8281.115Obesity prevalence14.97.4322.72613.16815.949Healthcare accessSenior assisted living rate (‰)150.6253.17415.911140.49153.134Density of physicians (‰~**∘∘**~)326.71894.24243.523299.047330.892Places in short hospitalization service248,711Hospitalization bed density (‰ES)387.5647.72725.45371.329390.705Sunlight exposure (accumulated, hours)2079.7557,890.461204.6041943.6152088.526InfectionConfirmed cases84,286Infection rate (%)0.118250.0070.0810.0650.299Recovered cases8047Recovery rate (%)50.89229.4155.42447.44652.372Deceased cases14,107Mortality rate (%)14.5837.6052.75812.83115.638

3.2. Outcomes {#sec0009}
-------------

The primary outcome of this analysis was the Pearson coefficient between sunlight exposure and COVID-19 mortality rate, for which we found a value of −0.6368. With a corresponding p-value 1.532×10^−32^, this allows us to reject the null hypothesis H~0~ ([Table 3](#tbl0003){ref-type="table"} ). In other words, we surmise that sunlight exposure may have a protective effect against COVID-19 mortality, with a p-value of 1.532×10^−32^.Table 3Pearson test between each variable and mortality rate.Table 3Pearson coefficientStudentP-value**Sex ratio**Male0.6637115.6017.396×10^−33^Female−0.663**Age**0--24y**NOT USED**25--59y\>60y**Life expectancy**−0.4854456.1667.971×10^−31^Male−0.4253773.2104.207×10^−30^Female−0.5244940.5272.841×10^−31^**Birth rateDeath rateTaxable income rate**0.1541252.2522.595×10^−25^**Health status**Current smokers prevalence−0.112905.5626.636×10^−24^Diabetic prevalence0.4393925.6522.831×10^−30^COPD prevalence0.4443981.2652.46×10^−30^Chronic kidney failure prevalence0.1941588.8802.4 × 10^−26^Obesity prevalence0.5625459.0601.047×10^−31^**Healthcare access**Senior assisted living rate0.4033537.9218.00×10^−30^Density of physicians−0.4033537.9218.00×10^−30^Short-term hospital beds−0.035281.3807.905×10^−19^Hospital beds−0.151218.9673.398×10^−25^**Sunlight exposure**−0.63686615.6801.532×10^−32^**COVID-19 infectionConfirmed cases**Infection rate0.6186315.7752.437×10^−32^**Healed cases**Recovery rate−0.3733229.9731.991×10^−29^**Deceased cases**Mortality rate**REFERENCE VARIABLE**

The secondary outcomes showed other variables significantly correlated with COVID-19 mortality:1.positively-correlated variables indicating a potential risk factor: being male (p-value: 7.396×10^−33^); higher rate of senior assisted living beds (p-value: 7.913×10^−30^); taxable income (p-value: 2.595×10^−25^);2.negatively-correlated variables indicative a potential protective effect: life expectancy (p-value: 7.951×10^−31^), current smoking status (p-value: 6.636×10^−24^), physician density (p-value: 7.921×10^−30^); hospital bed density (p-value: 3.398×10^−25^).

4. Discussion {#sec0010}
=============

We have shown via Pearson correlation that sunlight exposure is significantly correlated (p-value: 1.532×10^−32^) COVID-19 mortality rate in continental metropolitan France ([Table 3](#tbl0003){ref-type="table"}), which is the main outcome of this study.

Besides, we acknowledge an interesting secondary finding: namely, the protective effect of life expectancy (Pearson r: 0.512; p-value: 7.951×10^−31^) and discuss it further as it appears counterintuitive, as older age is already been broadly documented as being associated with worse COVID-19 outcomes. However, we also note that in our sample life expectancy is strongly positively correlated with sunlight exposure (Pearson r: 1.628×10^−3^; p-value: 3.88×10^−31^), which indicates that life expectancy is a mere surrogate of sunlight exposure in this data set, and can therefore be safely explained out of this analysis.

This study is of course limited by two important factors: (1) lack of measurement time; (2) lack of direct vitamin D measurements; (3) confounding variables. First, the brief duration (2 months) across which measurements were taken did not allow us to well understand the time-evolution of the evinced correlations, a crucial point indeed in the context of a pandemic. Secondly, our data set did not include a variable measuring actual plasma vitamin D levels in the studied population, for which we used sunlight exposure as an imperfect surrogate. Last but not least, we are also concerned by the influence of other co-factors well-known to be associated with poor prognosis in Intensive Care Unit population infected by COVID-19, such as high BMI or diabetes ([Table 3](#tbl0003){ref-type="table"}), and possibly other unknown population confounding variables.

Nevertheless, our regression, linked with the hypothesized physiopathological mechanism ([@bib0012]), suggests a first order effect at least. We thus contend that the findings presented in our analysis should be taken into account, in order to envision possibly effective yet inexpensive diagnostic and therapeutic options against the novel COVID-19.

Our conclusions could easily be tested and further assessed by screening the prevalence of COVID-19 infected among vitamin D deficient patients. In addition, in vitro cell studies and animal models could be of interest to test our statistical correlation and the physiopathological hypothesis.
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